Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a party drug ease PTSD?

NCT ID NCT06215261

Symptom relief Sponsor: Transcend Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called methylone in 62 adults with severe PTSD. Participants took methylone capsules once a week for 3 to 4 weeks. Researchers measured changes in PTSD and depression symptoms to see if the drug is safe and helpful.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methylone
What this could lead to
If it works, this could point toward a new treatment option for people with PTSD.
What could go wrong
This is a small, early-phase trial with only 62 participants. It may not work for everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

62 people

The number who actually took part.

Started

Apr 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meets DSM-5 criteria for severe PTSD diagnosis, with a symptom duration of at least 6 months. * Tried at least one treatment for PTSD (either psychotherapy or pharmacological treatment). * Proficient in reading and writing in local language sufficient to complete questionnaires. * Free from any other clinically significant illness or disease. Exclusion Criteria: * Primary diagnosis of any other DSM-5 disorder. * Body mass index (BMI) \<18kg/m2 or ≥40 kg/m2. * Smokes an average of \>10 cigarettes and/or e-cigarettes per day. * Uncontrolled hypertension at Screening. * Use of prohibited concomitant medications or therapies. * Current or previous history of clinically significant cardiovascular/cerebrovascular conditions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post traumatic stress disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post traumatic stress disorder

Contacts and locations

Locations

  • Accel Research

    Maitland, Florida, 32751, United States

  • CNS Healthcare

    Orlando, Florida, 32801, United States

  • Clerkenwell Health

    London, United Kingdom

  • Monarch Mental Health Group

    Melbourne, Victoria, Australia

  • Numinus

    Draper, Utah, 84020, United States

  • Ramsay Clinic Albert Road

    Melbourne, Victoria, 3004, Australia

  • Redbird Research LLC

    Las Vegas, Nevada, 89119, United States

  • Seattle NTC

    Bellevue, Washington, 98004, United States

  • Segal Trials

    Lauderhill, Florida, 33319, United States

  • Sunstone Medical

    Rockville, Maryland, 20850, United States

  • Swinburne University of Technology

    Hawthorn, Victoria, 3122, Australia

  • Uptown Clinical Research

    Chicago, Illinois, 60640, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.